- Home
- HHS vs GRCE Comparison
HHS vs GRCE Comparison
Compare HHS & GRCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHS
- GRCE
- Stock Information
- Founded
- HHS 1923
- GRCE 2002
- Country
- HHS United States
- GRCE United States
- Employees
- HHS N/A
- GRCE N/A
- Industry
- HHS Advertising
- GRCE
- Sector
- HHS Consumer Discretionary
- GRCE
- Exchange
- HHS Nasdaq
- GRCE NYSE
- Market Cap
- HHS 37.0M
- GRCE 40.0M
- IPO Year
- HHS N/A
- GRCE N/A
- Fundamental
- Price
- HHS $4.55
- GRCE $2.77
- Analyst Decision
- HHS
- GRCE Strong Buy
- Analyst Count
- HHS 0
- GRCE 1
- Target Price
- HHS N/A
- GRCE $12.00
- AVG Volume (30 Days)
- HHS 7.6K
- GRCE 29.0K
- Earning Date
- HHS 05-14-2025
- GRCE 06-10-2025
- Dividend Yield
- HHS N/A
- GRCE N/A
- EPS Growth
- HHS N/A
- GRCE N/A
- EPS
- HHS N/A
- GRCE N/A
- Revenue
- HHS $181,355,000.00
- GRCE N/A
- Revenue This Year
- HHS $6.54
- GRCE N/A
- Revenue Next Year
- HHS N/A
- GRCE N/A
- P/E Ratio
- HHS N/A
- GRCE N/A
- Revenue Growth
- HHS N/A
- GRCE N/A
- 52 Week Low
- HHS $4.24
- GRCE $1.75
- 52 Week High
- HHS $8.87
- GRCE $4.97
- Technical
- Relative Strength Index (RSI)
- HHS 46.53
- GRCE N/A
- Support Level
- HHS $4.53
- GRCE N/A
- Resistance Level
- HHS $4.94
- GRCE N/A
- Average True Range (ATR)
- HHS 0.31
- GRCE 0.00
- MACD
- HHS -0.00
- GRCE 0.00
- Stochastic Oscillator
- HHS 37.80
- GRCE 0.00
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About GRCE GRACE THERAPEUTICS INC
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.